Back

Voltage/mass ratio (VMR) prognosis value in heart failure (HF) patients with transthyretin cardiac amyloidosis (ATTR-CA).

1 December 2022 (13:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 1 Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Asia 2022 with APSC & AFC

About the speaker

Photo
Doctor Jerome Costa

Hospital Robert Debre - University Hospital Centre of Reims, Reims (France)

27 More presentations in this session

Presentation thumbnail
Frequent need for apixaban dose adjustment for atrial fibrillation in an unselected acute medical admission population during the COVID 19 pandemic.
Doctor K. Kyaw (Plymouth, GB)
Abstract Slides
Presentation thumbnail
The use of hatch score for the prediction of post operative atrial fibrillation (poaf) after coronary artery bypass graft: a meta-analysis
Doctor A. Ramos (Muntinlupa, PH)
Abstract Slides
Presentation thumbnail
Relationship and outcomes between volume status, cardiac and renal dysfunction in patients with chronic heart failure.
Doctor A. Challa (Rochester, US)
Abstract Slides
Presentation thumbnail
Association between triglyceride and all-cause mortality and cardiovascular outcomes in heart failure patients: a territory-wide study in Hong Kong
Mrs Q. Ren (Hong Kong, HK)
Abstract Slides
Presentation thumbnail
Effects of SGLT2 inhibitors on heart failure symptoms, quality of life and exercise capacity in patients with heart failure and preserved ejection fraction: A meta-analysis
Doctor L. Merin (Cebu City, PH)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1

The Event

Event poster

ESC Asia 2022 with APSC & AFC

1 December 2022 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Accuracy of the discrepancy indices between QRS voltages on electrocardiogram and left ventricular mass in the diagnosis of amyloidosis: a sub-analysis of the AC-TIVE study
22 May 2023
thumbnail
Congress Presentation
NT-proBNP and cardiopulmonary exercise testing parameters for risk stratification in ATTR-CM
5 April 2025
thumbnail
Congress Presentation
The PA/Ao ratio as a predictor for adverse outcomes in light-chain vs. transthyretin cardiac amyloidosis
1 September 2025
thumbnail
Congress Presentation
Patients with transthyretin amyloid cardiomyopathy may have preserved, mildly reduced, or reduced ejection fraction
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources